睿知中国疾病研究地图
候选清单0

正在招募胃癌早期I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors

ClinicalTrials.gov 上登记的一项胃癌开放试验,由浙江大学医学院附属第一医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)浙江大学医学院附属第一医院First Affiliated Hospital, Zhejiang University杭州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06937567,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 70 岁;性别:不限

    登记记录的入选字段

  2. Tumor tissue must be available either from prior tumor biopsy or by providing new tumor specimens.

    入选标准第 4 条

  3. Non-hematological toxicity from prior treatment (surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc.) has not resolved to ≤ CTCAE grade 1 (except for hair loss and peripheral sensory neuropathy).

    排除标准第 6 条

    Patients who have previously received CDH17 CAR-T therapy, except those who received CAR-T infusion within this study.

    排除标准第 8 条

  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

    入选标准第 6 条

  5. At least one measurable lesion as defined by RECIST v1.1 criteria.

    入选标准第 3 条

  6. Positive hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb) with peripheral HBV DNA levels above the lower limit of detection.

    排除标准第 2 条

    Positive hepatitis C virus (HCV) antibody with peripheral HCV RNA levels above the lower limit of detection.

    排除标准第 3 条

    Positive HIV antibody.

    排除标准第 4 条

    History of another malignancy within the past 5 years, except for adequately treated non-melanoma skin cancer or in situ cancers.

    排除标准第 21 条

  7. Female participants of childbearing potential must have a negative pregnancy test.

    入选标准第 9 条

    Female participants of childbearing potential or male participants with partners of childbearing potential must agree to use effective contraception during the study and for 1 year after the final cell infusion.

    入选标准第 10 条

    Women who are pregnant or breastfeeding.

    排除标准第 1 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06937567,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Histopathologically confirmed malignant solid tumors, including but not limited to colorectal cancer, gastric cancer, pancreatic cancer, and biliary tract tumors.
  2. Patients must have failed standard treatments, be intolerant to standard treatments, or lack effective treatment options.
  3. At least one measurable lesion as defined by RECIST v1.1 criteria.
  4. Tumor tissue must be available either from prior tumor biopsy or by providing new tumor specimens.
  5. Tumor specimens must be confirmed as CDH17-positive by immunohistochemistry (IHC) or immunocytochemistry (ICC) staining.
  6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  7. Expected survival time ≥ 3 months.
  8. Appropriate organ function: hematological: Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; Absolute lymphocyte count (ALC) ≥ 0.5 × 10⁹/L. Hemoglobin (HGB) ≥ 80 g/L; Platelet count (PLT) ≥ 75 × 10⁹/L. Liver Function: aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤ 3.0 × ULN (≤ 5.0 × ULN for patients with primary liver tumors or liver metastases); total bilirubin ≤ 1.5 × ULN (≤ 3.0 × ULN for patients with primary liver tumors or liver metastases; ≤ 3 × ULN for Gilbert's syndrome with direct bilirubin ≤ 1.5 × ULN). Coagulation: international normalized ratio (INR) ≤ 1.5 × ULN (unless on therapeutic anticoagulants); activated partial thromboplastin time (APTT) ≤ 1.5 × ULN (unless on therapeutic anticoagulants). Renal Function: serum creatinine (Cr) ≤ 1.5 × ULN or creatinine clearance rate ≥ 60 mL/min (based on Cockcroft-Gault formula). Cardiac Function: left ventricular ejection fraction (LVEF) ≥ 50% (confirmed by echocardiography). Pulmonary Function: resting oxygen saturation (SpO₂) > 92% without supplemental oxygen.
  9. Female participants of childbearing potential must have a negative pregnancy test.
  10. Female participants of childbearing potential or male participants with partners of childbearing potential must agree to use effective contraception during the study and for 1 year after the final cell infusion.
  11. Willingness to sign the informed consent form, demonstrating understanding of the study and agreement to comply with study procedures.

排除标准:Exclusion Criteria:

  1. Women who are pregnant or breastfeeding.
  2. Positive hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb) with peripheral HBV DNA levels above the lower limit of detection.
  3. Positive hepatitis C virus (HCV) antibody with peripheral HCV RNA levels above the lower limit of detection.
  4. Positive HIV antibody.
  5. Positive syphilis-specific and non-specific antibody tests.
  6. Non-hematological toxicity from prior treatment (surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc.) has not resolved to ≤ CTCAE grade 1 (except for hair loss and peripheral sensory neuropathy).
  7. Prior allogeneic tissue or organ transplant (including bone marrow, stem cell, liver, kidney, etc.), except for transplants not requiring immunosuppression (e.g., corneal or hair transplantation).
  8. Patients who have previously received CDH17 CAR-T therapy, except those who received CAR-T infusion within this study.
  9. Underwent major surgery within 4 weeks prior to signing informed consent and has not fully recovered, or has a history of serious unresolved trauma.
  10. Known central nervous system (CNS) metastases (with exceptions for asymptomatic brain metastases or stable clinical symptoms).
  11. Severe active infections or pulmonary diseases requiring systemic corticosteroid treatment within 6 months prior to signing informed consent.
  12. Symptomatic congestive heart failure (NYHA class II-IV), severe aortic stenosis, or symptomatic mitral stenosis.
  13. ECG showing QTc > 450 ms or QTc > 480 ms with bundle branch block.
  14. Uncontrolled hypertension (SBP ≥ 160 mmHg and/or DBP ≥ 100 mmHg).
  15. Cerebrovascular accidents within 6 months prior to signing informed consent.
  16. Active, chronic, or recurrent severe autoimmune diseases requiring immunosuppressive treatment (with exceptions).
  17. Any form of primary or secondary immunodeficiency.
  18. Risk of organ perforation or bleeding as judged by the investigator.
  19. Severe systemic hypersensitivity reactions to study drugs/components. - Received live attenuated vaccines within 4 weeks prior to signing informed consent.
  20. Participated in another clinical study within 4 weeks prior to signing informed consent.
  21. History of another malignancy within the past 5 years, except for adequately treated non-melanoma skin cancer or in situ cancers.
  22. Diagnosed with neuropsychiatric disorders or any condition deemed by the investigator as unsuitable for participation.

引自 ClinicalTrials.gov, NCT06937567, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06937567,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06937567